Perspective
Generic and therapeutic orphans
Abstract: This commentary discusses the need to develop methods to ensure the availability of non-profitable, off-patent medicines to children and other populations. The history and some of the shortcomings of… Read More »
Myths, questions, facts about generic drugs in the EU
Abstract: Many generic drugs are now being prescribed and the trend is increasing. For example, in Austria, the number of all generics prescriptions has more than doubled from 11% in… Read More »
Current understanding, knowledge, and perception of biosimilars in a changing landscape of regulatory requirements
Author byline as per print journal: Andriy Krendyukov, MD, PhD; Marta Bakowska, BA (Hon), MPH; Dirk Schiller, PhD; Sanjay Singhvi, BSc (Hon), MBBS, MBA Introduction: Healthcare providers often lack familiarity… Read More »
Comparative efficacy studies of biosimilars: data versus theoretical risks, beliefs, and comfort
Abstract: Ethnic sensitivity assessments in the form of bridging pharmacokinetics (PK) studies are often needed for biosimilar monoclonal antibodies (mAbs) to meet regulatory requirements in regions like East Asia.… Read More »